✦ LIBER ✦

Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan

✍ Scribed by Y.-K. Soong, K.-S. Tsai, H.-Y. Huang, R.-S. Yang, J.-F. Chen, P. C.-H. Wu, K.-E. Huang

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The association between compliance and p

✍ Jonathan Adachi; Niall Lynch; Hans Middelhoven; Manjit Hunjan; Warren Cowell 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 250 KB

Improving Compliance and Persistence wit

✍ Ronald D. Emkey; Mark Ettinger 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 228 KB

PMS5 PERSISTENCE WITH BISPHOSPHONATE THE

✍ G. Chodick; V. Shalev; Y. Sharon; I. Goldstein 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PERSISTENCE WITH BISPHOSPHONATE THERAPY

✍ Magda Melo; Feng Qiu; Kathy Sykora; David Juurlink; Andreas Laupacis; Muhammad M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

Impact of compliance and persistence wit

✍ J. A. Sunyecz; L. Mucha; O. Baser; C. E. Barr; M. M. Amonkar 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 151 KB

Oral bisphosphonates are associated with

✍ H. Gothe; Hoer; V. Barghout; G. Schiffhorst; B. Haeussler 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 138 KB